Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
2.
Rev Mal Respir ; 14(5): 405-7, 1997 Nov.
Article in French | MEDLINE | ID: mdl-9480488

ABSTRACT

Bromocriptine, used in the treatment of acromegaly, hyperprolactinemia and Parkinson's disease, may be responsible in this last case, for pleuro-pulmonary complications in higher doses. Since 1981 about thirty cases were described. It was mostly pleural effusions, pleural thickening and parenchymal lung fibrosis. The prevalence of pleuro-pulmonary diseases is between 2 to 5% after 5 years with bromocriptine that varied in dosage from 20 to 90 mg daily. The patients developed symptoms from nine months to four years. We report a case of a patient treated for one year for Parkinson's disease with daily dose of 105 mg of bromocriptine in whom bilateral pulmonary infiltrate was discovered with a deterioration in the general physical state and dyspnea. There was a favorable clinical and chest roentgenogram outcome following the cessation of treatment, in six months. The hypotheses to explain the pathogenesis of these disorders were always discussed: a vascular theory, an immunological theory or a toxic fibrogenesis induced by the molecule acting on dopaminergic receptors and serotonergic synapses. Now, in our knowledge, these complications justify a clinical and chest roentgenogram follow up for any patients treated with bromocriptine.


Subject(s)
Antiparkinson Agents/adverse effects , Bromocriptine/adverse effects , Lung Diseases, Interstitial/chemically induced , Aged , Antiparkinson Agents/administration & dosage , Bromocriptine/administration & dosage , Bronchoalveolar Lavage Fluid , Follow-Up Studies , Humans , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/diagnostic imaging , Male , Radiography, Thoracic , Time Factors , Tomography, X-Ray Computed
5.
J Reprod Fertil ; 54(1): 133-6, 1978 Sep.
Article in English | MEDLINE | ID: mdl-712700

ABSTRACT

Mink were mated between 17 February and 22 March. In females kept in natural daylight concentrations of progesterone, measured by radioimmunoassay, began to rise between 25 and 30 March, whatever the date of mating. After reaching peak values of 40--160 ng/ml, progesterone concentrations decreased before the end of pregnancy. In females given 14 h light/24 h immediately after mating, the rise of progesterone began a few days earlier, indicating that the extra light induces earlier progesterone secretion, nidation and parturition.


Subject(s)
Embryo Implantation , Light , Mink/physiology , Progesterone/blood , Animals , Female , Mink/blood
SELECTION OF CITATIONS
SEARCH DETAIL